TGFBR1 and urinary bladder cancer: This process is reversed by SENP2 (SUMO-specific protease-2), which removes SUMO from TGFBR1, thereby inhibiting TGF-β1-induced EMT, resulting in inhibition of the invasion of bladder cancer cells in vitro and tumor metastasis in vivo.